SourceBio International PLC Notice of Results (5264W)

TIDMSBI

RNS Number : 5264W

SourceBio International PLC

19 August 2022

SourceBio International plc

('SourceBio', the 'Company' or the 'Group')

Notice of Half Year Results

and

Investor presentation

SourceBio International plc (AIM: SBI), a leading international provider of integrated state-of-the-art laboratory services , announces that its unaudited half year results for the six months ended 30 June 2022 are expected to be released on 8 September 2022.

Investor Presentation

Jay LeCoque, Executive Chairman, and Tony Ratcliffe, Chief Financial Officer, will provide a live presentation on the Half Year Results via the Investor Meet Company platform on the following day, 9th September 2022, at 9:30am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet SourceBio International plc via:

https://www.investormeetcompany.com/sourcebio-international-plc/register-investor

Investors who already follow SourceBio International plc on the Investor Meet Company platform will automatically be invited.

Contacts:

 
 SourceBio International plc                            www.sourcebiointernational.com 
 Jay LeCoque, Executive Chairman                                       Via Walbrook PR 
 Tony Ratcliffe, Chief Financial Officer 
 
 Liberum (Nominated Advisor and Broker)                             Tel: [phone] 
 Richard Lindley / William Hall / Miquela 
  Bezuidenhoudt 
 
 Walbrook PR Limited                    Tel: [phone] or [e-mail] 
 Paul McManus / Sam Allen                                   Mob: [phone] / 07502 
                                                                               558 258 
 
 

About SourceBio International plc www.sourcebiointernational.com

SourceBio is a leading international provider of integrated state-of-the-art laboratory services with clients in the pharmaceutical, healthcare, clinical, drug development and life sciences research industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four business units:

 
 --   Healthcare Diagnostics - Histopathology cancer screening, including 
       Digital Pathology and clinical diagnostic services for the NHS and 
       private healthcare providers across the UK 
 --   Genomics - DNA sequencing services and Precision Medicine offering 
       for pharmaceutical and biotechnology industries, academia, contract 
       research organisations (CROs) and other research groups in the UK, 
       Europe and North America 
     ---------------------------------------------------------------------- 
 --   Stability Storage Controlled environmental storage services and 
       laboratory equipment validation services for pharmaceutical industry 
       in the UK, Ireland and North America 
     ---------------------------------------------------------------------- 
 --   Infectious Disease Testing - A range of COVID-19 testing services 
       for commercial enterprises, private healthcare groups and the NHS, 
       including PCR testing under ISO 15189 accreditation. 
     ---------------------------------------------------------------------- 
 

More details on Group operations can be found here: www.sourcebioscience.com

SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORQVLFFLVLBBBB

(END) Dow Jones Newswires

August 19, 2022 02:00 ET (06:00 GMT)